Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging therapeutic opportunities

Frontiers in Physiology

Volumn 5, Issue Nov, 2014, Pages

  Hubbard, Paul A ^a   Moody, Colleen ^a   Murali, Ramachandran ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allostery; Drug design; k Ras; Kinase inhibitor; Pancreatic cancer; PI3K AKT mTOR pathway

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; IDELALISIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLECKSTRIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR;

ALLOSTERISM; ARTICLE; CANCER GROWTH; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84911921917     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00478     Document Type: Article

References (62)

1. Agarwal, E., Brattain, M.G., and Chowdhury, S. (2013). Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 25, 1711-1719. doi: 10.1016/j.cellsig.2013.03.025.
2. Ahmadian, M.R., Zor, T., Vogt, D., Kabsch, W., Selinger, Z., Wittinghofer, A., and Scheffzek, K. (1999). Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci U S A 96, 7065-7070.
3. Barnett, S.F., Bilodeau, M.T., and Lindsley, C.W. (2005a). The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem 5, 109-125.
4. Barnett, S.F., Defeo-Jones, D., Fu, S., Hancock, P.J., Haskell, K.M., Jones, R.E., Kahana, J.A., Kral, A.M., Leander, K., Lee, L.L., Malinowski, J., Mcavoy, E.M., Nahas, D.D., Robinson, R.G., and Huber, H.E. (2005b). Identification and characterization of pleckstrin-homology-domain dependent and isoenzyme-specific Akt inhibitors. Biochem J 385, 399-408. doi: 10.1042/BJ20041140.
5. Burke, J.E., Perisic, O., Masson, G.R., Vadas, O., and Williams, R.L. (2012). Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A 109, 15259-15264. doi: 10.1073/pnas.1205508109.
6. Burke, J.E., Vadas, O., Berndt, A., Finegan, T., Perisic, O., and Williams, R.L. (2011). Dynamics of the phosphoinositide 3-kinase p110delta interaction with p85alpha and membranes reveals aspects of regulation distinct from p110alpha. Structure 19, 1127-1137. doi: 10.1016/j.str.2011.06.003.
7. Califano, R., Landi, L., and Cappuzzo, F. (2012). Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 72 Suppl 1, 28-36. doi: 10.2165/1163012-S0-000000000-00000.
8. Castellano, E., and Downward, J. (2010). Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 346, 143-169. doi: 10.1007/82_2010_56.
9. Chang, F., Lee, J.T., Navolanic, P.M., Steelman, L.S., Shelton, J.G., Blalock, W.L., Franklin, R.A., and Mccubrey, J.A. (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603. doi: 10.1038/sj.leu.2402824.
10. Collins, I. (2009). Targeted small-molecule inhibitors of protein kinase B as anticancer agents. Anticancer Agents Med Chem 9, 32-50.
11. Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., Michalski, C.W., Schlitter, A.M., Esposito, I., Kind, A.J., Rad, L., Schnieke, A.E., Baccarini, M., Alessi, D.R., Rad, R., Schmid, R.M., Schneider, G., and Saur, D. (2013). Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23, 406-420. doi: 10.1016/j.ccr.2013.01.023.
12. Garcia-Echeverria, C., and Sellers, W.R. (2008). Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526. doi: 10.1038/onc.2008.246.
13. Giordanetto, F., Kull, B., and Dellsen, A. (2011). Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening. Bioorg Med Chem Lett 21, 829-835. doi: 10.1016/j.bmcl.2010.11.087.
14. Giordanetto, F., Wallberg, A., Cassel, J., Ghosal, S., Kossenjans, M., Yuan, Z.Q., Wang, X., and Liang, L. (2012). Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110beta isoform inhibitors through structure-based fragment optimisation. Bioorg Med Chem Lett 22, 6665-6670. doi: 10.1016/j.bmcl.2012.08.101.
15. Grant, B.J., Lukman, S., Hocker, H.J., Sayyah, J., Brown, J.H., Mccammon, J.A., and Gorfe, A.A. (2011). Novel allosteric sites on Ras for lead generation. PLoS One 6, e25711. doi: 10.1371/journal.pone.0025711.
16. Gysin, S., Salt, M., Young, A., and Mccormick, F. (2011). Therapeutic strategies for targeting ras proteins. Genes Cancer 2, 359-372. doi: 10.1177/1947601911412376.
17. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013.
18. Hon, W.C., Berndt, A., and Williams, R.L. (2012). Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 31, 3655-3666. doi: 10.1038/onc.2011.532.
19. Huang, S., Bjornsti, M.A., and Houghton, P.J. (2003). Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2, 222-232.
20. Hughes, S.J., Millan, D.S., Kilty, I.C., Lewthwaite, R.A., Mathias, J.P., O'reilly, M.A., Pannifer, A., Phelan, A., Stuhmeier, F., Baldock, D.A., and Brown, D.G. (2011). Fragment based discovery of a novel and selective PI3 kinase inhibitor. Bioorg Med Chem Lett 21, 6586-6590. doi: 10.1016/j.bmcl.2011.07.117.
21. Inoki, K., Li, Y., Xu, T., and Guan, K.L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17, 1829-1834. doi: 10.1101/gad.1110003.
22. John, J., Rensland, H., Schlichting, I., Vetter, I., Borasio, G.D., Goody, R.S., and Wittinghofer, A. (1993). Kinetic and structural analysis of the Mg(2+)-binding site of the guanine nucleotide binding protein p21H-ras. J Biol Chem 268, 923-929.
23. John, J., Sohmen, R., Feuerstein, J., Linke, R., Wittinghofer, A., and Goody, R.S. (1990). Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. Biochemistry 29, 6058-6065.
24. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M.D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17, 615-675. doi: 10.1146/annurev.cellbio.17.1.615.
25. Kelly, G.L., and Strasser, A. (2011). The essential role of evasion from cell death in cancer. Adv Cancer Res 111, 39-96. doi: 10.1016/B978-0-12-385524-4.00002-7.
26. Kim, J., Reber, H.A., Dry, S.M., Elashoff, D., Chen, S.L., Umetani, N., Kitago, M., Hines, O.J., Kazanjian, K.K., Hiramatsu, S., Bilchik, A.J., Yong, S., Shoup, M., and Hoon, D.S.B. (2006). Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 55, 1598-1605. doi: 10.1136/gut.2005.083063.
27. Knight, Z.A., Gonzalez, B., Feldman, M.E., Zunder, E.R., Goldenberg, D.D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., Balla, T., Weiss, W.A., Williams, R.L., and Shokat, K.M. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733-747. doi: 10.1016/j.cell.2006.03.035.
28. Kohl, N.E., Wilson, F.R., Mosser, S.D., Giuliani, E., Desolms, S.J., Conner, M.W., Anthony, N.J., Holtz, W.J., Gomez, R.P., Lee, T.J., and et al. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 91, 9141-9145.
29. Kumar, C.C., and Madison, V. (2005). AKT crystal structure and AKT-specific inhibitors. Oncogene 24, 7493-7501. doi: 10.1038/sj.onc.1209087.
30. Lindsley, C.W., Zhao, Z., Leister, W.H., Robinson, R.G., Barnett, S.F., Defeo-Jones, D., Jones, R.E., Hartman, G.D., Huff, J.R., Huber, H.E., and Duggan, M.E. (2005). Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15, 761-764. doi: 10.1016/j.bmcl.2004.11.011.
31. Lingham, R.B., Silverman, K.C., Jayasuriya, H., Kim, B.M., Amo, S.E., Wilson, F.R., Rew, D.J., Schaber, M.D., Bergstrom, J.D., Koblan, K.S., Graham, S.L., Kohl, N.E., Gibbs, J.B., and Singh, S.B. (1998). Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase. J Med Chem 41, 4492-4501. doi: 10.1021/jm980356+.
32. Liu, P., Cheng, H., Roberts, T.M., and Zhao, J.J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8, 627-644. doi: 10.1038/nrd2926.
33. Malumbres, M., and Pellicer, A. (1998). RAS pathways to cell cycle control and cell transformation. Front Biosci 3, d887-912.
34. Maurer, T., Garrenton, L.S., Oh, A., Pitts, K., Anderson, D.J., Skelton, N.J., Fauber, B.P., Pan, B., Malek, S., Stokoe, D., Ludlam, M.J., Bowman, K.K., Wu, J., Giannetti, A.M., Starovasnik, M.A., Mellman, I., Jackson, P.K., Rudolph, J., Wang, W., and Fang, G. (2012). Small molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 109, 5299-5304. doi: 10.1073/pnas.1116510109.
35. May, S., Kashishian, A., Lin, T., and Al, E. (Year). "CAL-101, a selective inhibitor of the p110d isoform of phosphatidylinositol 3-kinase, effectively induces apoptosis in primary chronic lymphocytic leukemia cells providing a novel therapeutic strategy for the treatment of this disease.", in: ASH Annual Meeting), Abstract 3165.
36. Milburn, M.V., Tong, L., Devos, A.M., Brunger, A., Yamaizumi, Z., Nishimura, S., and Kim, S.H. (1990). Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247, 939-945.
37. Morris, J.P.T., Wang, S.C., and Hebrok, M. (2010). KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10, 683-695. doi: 10.1038/nrc2899.
38. O'reilly, K.E., Rojo, F., She, Q.-B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L., Baselga, J., and Rosen, N. (2006). mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research 66, 1500-1508. doi: 10.1158/0008-5472.can-05-2925.
39. Okuzumi, T., Fiedler, D., Zhang, C., Gray, D.C., Aizenstein, B., Hoffman, R., and Shokat, K.M. (2009). Inhibitor hijacking of Akt activation. Nat Chem Biol 5, 484-493. doi: 10.1038/nchembio.183.
40. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., and Shokat, K.M. (2013). K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551. doi: 10.1038/nature12796.
41. Pai, E.F., Kabsch, W., Krengel, U., Holmes, K.C., John, J., and Wittinghofer, A. (1989). Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341, 209-214. doi: 10.1038/341209a0.
42. Pérez-Ruiz, E., Rueda, A., Pereda, T., Alcaide, J., Bautista, D., Rivas-Ruiz, F., Villatoro, R., Pérez, D., and Redondo, M. (2012). Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. Tumor Biology 33, 1829-1835. doi: 10.1007/s13277-012-0442-z.
43. Prive, G.G., Milburn, M.V., Tong, L., De Vos, A.M., Yamaizumi, Z., Nishimura, S., and Kim, S.H. (1992). X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis. Proc Natl Acad Sci U S A 89, 3649-3653
44. Reuveni, H., Livnah, N., Geiger, T., Klein, S., Ohne, O., Cohen, I., Benhar, M., Gellerman, G., and Levitzki, A. (2002). Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41, 10304-10314.
45. Rodriguez-Viciana, P., Warne, P.H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M.J., Waterfield, M.D., and Downward, J. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532. doi: 10.1038/370527a0.
46. Sabatini, D.M. (2006). mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6, 729-734. doi: 10.1038/nrc1974.
47. Santi, S.A., and Lee, H. (2010). The Akt isoforms are present at distinct subcellular locations. Am J Physiol Cell Physiol 298, C580-591. doi: 10.1152/ajpcell.00375.2009.
48. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D.M. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302. doi: 10.1016/j.cub.2004.06.054.
49. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L., and Sabatini, D.M. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168. doi: 10.1016/j.molcel.2006.03.029.
50. Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101. doi: 10.1126/science.1106148.
51. Sawyers, C.L. (2009). Finding and drugging the vulnerabilities of RAS-dependent cancers. Cell 137, 796-798. doi: 10.1016/j.cell.2009.05.011.
52. Scheffzek, K., Ahmadian, M.R., Kabsch, W., Wiesmuller, L., Lautwein, A., Schmitz, F., and Wittinghofer, A. (1997). The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338.
53. Sun, Q., Burke, J.P., Phan, J., Burns, M.C., Olejniczak, E.T., Waterson, A.G., Lee, T., Rossanese, O.W., and Fesik, S.W. (2012). Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 51, 6140-6143. doi: 10.1002/anie.201201358.
54. Traut, T. (1994). Physiological concentrations of purines and pyrimidines. Molecular and Cellular Biochemistry 140, 1-22. doi: 10.1007/BF00928361.
55. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11, 329-341. doi: 10.1038/nrm2882.
56. Vezina, C., Kudelski, A., and Sehgal, S.N. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28, 721-726.
57. Wennerberg, K., Rossman, K.L., and Der, C.J. (2005). The Ras superfamily at a glance. J Cell Sci 118, 843-846. doi: 10.1242/jcs.01660.
58. Whyte, D.B., Kirschmeier, P., Hockenberry, T.N., Nunez-Oliva, I., James, L., Catino, J.J., Bishop, W.R., and Pai, J.K. (1997). K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272, 14459-14464.
59. Wu, W.I., Voegtli, W.C., Sturgis, H.L., Dizon, F.P., Vigers, G.P., and Brandhuber, B.J. (2010). Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 5, e12913. doi: 10.1371/journal.pone.0012913.
60. Yan, L. (2009). Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. AACR Meeting Abstracts 2009, DDT01-01-.
61. Yang, H., Rudge, D.G., Koos, J.D., Vaidialingam, B., Yang, H.J., and Pavletich, N.P. (2013). mTOR kinase structure, mechanism and regulation. Nature 497, 217-223. doi: 10.1038/nature12122.
62. Zhang, X., Vadas, O., Perisic, O., Anderson, K.E., Clark, J., Hawkins, P.T., Stephens, L.R., and Williams, R.L. (2011). Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 41, 567-578. doi: 10.1016/j.molcel.2011.01.026.